Abivax SA

ABIVAX is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of novel anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
  • TickerABVX
  • ISINFR0012333284
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

GlobalData Department

Abivax SA (ABVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Abivax SA (Abivax) is a biotechnology company that develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce functional cure in HIV-patients and inflammatory bowel diseases caused by a dysregulated immune response to host intestinal microflora. Abivax’s ABX544 focuses on the production and purification of neutralizing antibodies from immunized animals with specific antigen for the treatment for EBOLA virus...

Anita Ye ...
  • Dylan van Haaften

ABIVAX - Penguins on an ice floe around excellent UC data, increasing TP to €21

Anita Ye ...
  • Dylan van Haaften

ABIVAX - UC data much better than expected, looking forward to Crohn’s and partnering

Anita Ye ...
  • Dylan van Haaften

ABIVAX - Takeaways from our HIV KOL event during the Amsterdam AIDS conference

Anita Ye ...
  • Dylan van Haaften

The devil in the details: a nuanced read of ABX464-005, hints at some optimism for phase IIb

Christophe DOMBU

Deuxième étude de phase 2a avec ABX464 dans le VIH

Abivax vient de recevoir l’aval des autorités réglementaires pour mener une étude de phase 2a en Europe, avec son produit ABX464 indiqué pour le traitement des infections au VIH. Cette étude intervient après la publication de résultats positifs d’une première étude de phase 2a établissant la première preuve d’efficacité de ce médicament first-in-class chez l’homme. La société compte ainsi renforcer l’attractivité de son produit phare en démontrant son potentiel pour la guérison fonctionnelle de la maladie. Les premiers résultats pourraient être communiqués dès la fin de l’année et permettront ...

1 director sold

A director at Abivax sold 16,374 shares at 7.429EUR and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Insider sold: A director sold 3,588 shares at 5.936EUR and

A director at Abivax sold 3,588 shares at 5.936EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board mem...

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

GlobalData Department

Abivax SA (ABVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary Abivax SA (Abivax) is a biotechnology company that develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious and viral diseases. The company’s pipeline products include ABX464, ABX544 and ABX196. Its ABX464 is an oral small molecule to induce functional cure in HIV-patients and inflammatory bowel diseases caused by a dysregulated immune response to host intestinal microflora. Abivax’s ABX544 focuses on the production and purification of neutralizing antibodies from immunized animals with specific antigen for the treatment for EBOLA virus...

Jehanne Leroy

Proxy Report - 15/06/2018

Proxinvest attire l'attention des actionnaires sur plusieurs points. Tout d'abord Proxinvest félicite la société pour avoir mis en place un conseil d'administration majoritairement indépendant d'après Proxinvest avec un taux d'indépendance de 56%. Cependant Proxinvest regrette que la société se permette d'utiliser ses augmentations de capital pendant les périodes d'offre publique, ce qui est d'après Proxinvest un dispositif anti-OPA. Enfin concernant les rémunérations du Directeur Général, Proxinvest regrette du manque de transparence et des montants qui excèdent la médiane des rémunération...

Etude de l'AG du 23/06/2017

Cette année, la Société offre un vote contraignant sur la politique de rémunération 2017 de son Directeur Général pour la première fois et dans le cadre de la nouvelle loi "Sapin II" (résolution 14). Proxinvest recommande aux actionnaires de s’opposer à cette résolution étant donné que la Société ne communique pas la politique de rémunération de son dirigeant pour l’exercice, ni les montants qui y sont attachés. En ce qui concerne les autorisations d'augmentation du capital, la Société ne suspend toujours pas ces opérations en période d'offre publique. Ces résolutions peuvent donc être assimi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch